Stephen Wolpe, Ph. D.
Stephen D. Wolpe, Ph.D. – Steve received his undergraduate degree from Amherst College and his Ph.D. from the University of Pennsylvania. He conducted post-doctoral work at Rockefeller University, where he discovered a group of proteins called chemokines that are important mediators in immunology and inflammatory disease. After his post-doctoral work, Dr. Wolpe joined Genetics Institute (which is now part of Pfizer), where he worked on a variety of projects in hematology, inflammatory diseases and stem cell biology.
In 1993 Steve joined the Wellstat family of companies, a group of privately-held biopharmaceutical companies whose CEO also founded Amgen, Applied Biosystems and IGEN/Bioveris. Steve led the largest research group at Wellstat and provided research support across all five companies - Therapeutics, Diagnostics, Biologics, Vaccines and Ophthalmics. Steve's group played a major role in developing a novel drug for diabetes, leading to a $350 million dollar development deal in 2009 between Wellstat and Sanofi. In addition to his research work, Steve also worked closely with the CEO in business development, intellectual property assessment and licensing across all the companies. Steve left Wellstat in 2010 and worked as a biotech consultant for a number of different biotech companies in the US, Israel and Russia before joining BHI as an Entrepreneur-in-Residence. Steve has published 28 articles in the peer-reviewed literature and is an inventor on over 50 patents, primarily in the areas of stem cells, inflammatory disease and diabetes.